Impact of Cyanoacrylate Glue on PICC Line Dressing Care

Sponsor
Columbia University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05246709
Collaborator
(none)
60
1
2
9
6.6

Study Details

Study Description

Brief Summary

This study will evaluate whether applying micro drops of cyanoacrylate glue to the participant's peripherally inserted central catheter (PICC) insertion site prior to covering the area of PICC line with a transparent film dressing will make the PICC dressing last longer and prevent an occurrence of PICC line moving out of its original placement. The investigators aims to evaluate whether 1) using the cyanoacrylate glue will lengthen the time to first dressing change; and 2) participants in the experimental arm (glue used) will have fewer dressing changes per week compared to the control arm (standard care) during admission.

Condition or Disease Intervention/Treatment Phase
  • Device: Cyanoacrylate glue
  • Device: Standard transparent film dressing
N/A

Detailed Description

The neonatal population poses a unique challenge due to the small surface area of PICC sites, underdeveloped skin layer, and inability to contain the child's movements during a dressing change.

PICC line migration is the most common complication of PICC line maintenance in the neonatal intensive care unit (NICU). Previous studies have found that the PICC migration/dislodgment mostly occurs during PICC dressing changes among the neonatal population.

Recent published studies demonstrated that medical tissue adherence glue, Cyanoacrylate, significantly reduces the incidences of catheter migration and insertion site bleeding of PICC lines in all age of patients including premature infants.

The proposed study is a randomized control study with aimed data collection of 60 participants; of the 60 participants, 50 participants' data are to be used for statistical analysis and additional 10 participants to account for withdrawals.

The participants will be randomly assigned to one of two groups: one (the control group) receiving our standard PICC dressing method and the other (the study group) receiving cyanoacrylate glue at the PICC insertion sites prior to applying a standard transparent film dressing over the PICC sites.

The control group will reflect standard practice of PICC insertion and dressings using a standard transparent polyurethane film dressing, 3M TEGADERM Film.

The study group will reflect the application of a few drops of cyanoacrylate glue, SecurePortIVTM by Adhezion Biomedical® at the insertion sites prior to dressing a PICC line area with a standard transparent polyurethane film dressing.

The aim for this study is to investigate whether the application of cyanoacrylate glue at the insertion sites prior to dressing a PICC line area with a standard dressing will increase the longevity of the PICC line dressing and reduce the incidences of PICC line migration.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
60 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Randomized control studyRandomized control study
Masking:
None (Open Label)
Primary Purpose:
Other
Official Title:
Randomized Control Study to Evaluate Impact of the Use of Cyanoacrylate Glue on PICC Line Dressing Care in the Infant Cardiac Care Unit at Children's Hospital of New York
Anticipated Study Start Date :
Mar 1, 2022
Anticipated Primary Completion Date :
Dec 1, 2022
Anticipated Study Completion Date :
Dec 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Control Group

This group will be received the current standard of care (SOC) dressing method for PICC lines.

Device: Standard transparent film dressing
A standard transparent polyurethane film dressing, such as 3M TEGADERM Film, for dressing the PICC line area.

Experimental: Cyanoacrylate Glue Group

This group will receive a few drops of cyanoacrylate glue on PICC line site prior to application of usual standard film dressing over the PICC line site.

Device: Cyanoacrylate glue
Adhesive to be applied on the PICC line site prior to usual standard film dressing over the site, such as SecurePortIV® Catheter Securement Adhesive by Adhezion Biomedical® Cyanoacrylate adhesive that is FDA-approved for securement of vascular access devices. Securement method that provides microbial protection by sealing the insertion site.
Other Names:
  • SecurePortIV® Catheter Securement Adhesive
  • Device: Standard transparent film dressing
    A standard transparent polyurethane film dressing, such as 3M TEGADERM Film, for dressing the PICC line area.

    Outcome Measures

    Primary Outcome Measures

    1. Duration of longevity of PICC line dressing [Up to 7 days]

      Duration of longevity defined as the number of days the PICC line dressing lasts from the scheduled dressing change.

    Secondary Outcome Measures

    1. PICC line migration incidences [Until PICC line removal (approximately 12 weeks)]

      The incidence of PICC line migration defined as a change in the length of catheter extruding from the insertion site - a catheter migration of more than 0.25 cm will be counted as an incidence.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    1 Day to 6 Months
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • All patients admitted to the 9 North intensive coronary care unit (ICCU) at NewYork-Presbyterian Morgan Stanley Children's Hospital greater than 35 weeks of corrected gestational age who have a PICC line placed by a NICU provider.
    Exclusion Criteria:
    • Any patient with a PICC line in situ from an outside hospital.

    • Any patient with a PICC line placed by an outside department, namely the interventional radiology department.

    • Any patient with a PICC line that is silicon material catheter, such as Vygon Epicutaneo-Cava catheter because of limited accuracy of measuring a movement of the catheter migration after 25 centimeter mark due to absence of a centimeter mark on the catheter.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 NewYork-Presbyterian Morgan Stanley Children's Hospital at CUIMC New York New York United States 10032

    Sponsors and Collaborators

    • Columbia University

    Investigators

    • Principal Investigator: Marianne Garland, MD, Morgan Stanley Children's Hospital of NYP

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Marianne Garland, Neonatologist, Columbia University
    ClinicalTrials.gov Identifier:
    NCT05246709
    Other Study ID Numbers:
    • AAAT5997
    First Posted:
    Feb 18, 2022
    Last Update Posted:
    Feb 18, 2022
    Last Verified:
    Feb 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    Yes
    Plan to Share IPD:
    Yes
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    Yes
    Product Manufactured in and Exported from the U.S.:
    No
    Keywords provided by Marianne Garland, Neonatologist, Columbia University
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Feb 18, 2022